Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES

    NOTICE OF INTENT TO AWARD MULTIPLE BLANKET PURCHASE AGREEMENTS FOR STERILELY COMPOUNDED PHARMACEUTICALS VIA 503B COMPOUNDING PHARMACIES FOR GALLUP INDIAN MEDICAL CENTER

    Sol. NOI-GSUT2-20260003Special NoticeWINDOW ROCK, AZ
    Closed
    STATUS
    Closed
    closed Feb 18, 2026
    POSTED
    Feb 3, 2026
    Publication date
    NAICS CODE
    325412
    Primary industry classification
    PSC CODE
    6505
    Product & service classification

    AI Summary

    The Gallup Indian Medical Center intends to award multiple Blanket Purchase Agreements for sterilely compounded pharmaceuticals from FDA-designated 503B facilities. The products include various medications, and the anticipated performance period is one year with an option for an additional year. Interested vendors are encouraged to submit capability statements by 10:00 AM (MST) on February 18, 2026.

    Contract details

    Solicitation No.
    NOI-GSUT2-20260003
    Notice Type
    Special Notice
    Posted Date
    February 3, 2026
    Response Deadline
    February 18, 2026
    NAICS Code
    325412AI guide
    PSC / Class Code
    6505
    Primary Contact
    Rodney Brown
    State
    AZ
    ZIP Code
    86515
    AI Product/Service
    product

    Description

    Notice of Intent to Award – Multiple Blanket Purchase Agreements

    The Navajo Area Indian Health Service, Gallup Service Unit in Gallup, NM, intends to place multiple-award Blanket Purchase Agreements (BPA) with Fagron Compounding Services LLC (UEI: F7QNV46N18Q4) and American National Services LLC (UEI: LDNAY53JNV24) for sterilely compounded pharmaceuticals from an FDA-designated 503B facility on an as-needed basis. Items include Phenylephrine 100mcg.ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytoxin 30 units in 500ml (sterile to sterile and API), Epinephrine 8mg per 250ml bag (or other strength/volumes of the same medications in IV bags as available and required on an as-needed basis). Products must be sterilely compounded in an FDA approved facility with a beyond use date of at least 30 days from manufacture.

    The anticipated period of performance is a base period of one year from the date of award with one option period. The applicable North American Industry Classification System (NAICS) code assigned to this procurement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1,300 employees.

    No further awards will be made unless the need for Gallup Indian Medical Center changes. The prospective, multiple-award BPAs as identified in this notice are sufficient at this time.  In accordance with Part 12.201-1(e)(3)(i)(A), establishment of multiple BPAs constitute maximum practicable competition.

    Any other sources that believe they are capable of fulfilling the government requirements as described are encouraged to submit their capability statement, price lists, and catalogs to the point of contact listed below via email only and no later than 10:00AM (MST) on 2/18/2026. In the event additional BPAs are deemed to be in the best interest of the government, capable vendors may be contacted and be requested to establish a BPA with the Government.

    This notice of intent is not a request for quotations and a solicitation will not be issued.

    Key dates

    1. February 3, 2026Posted Date
    2. February 18, 2026Proposals / Responses Due

    AI search tags

    Frequently asked questions

    NOTICE OF INTENT TO AWARD MULTIPLE BLANKET PURCHASE AGREEMENTS FOR STERILELY COMPOUNDED PHARMACEUTICALS VIA 503B COMPOUNDING PHARMACIES FOR GALLUP INDIAN MEDICAL CENTER is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.